{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T09:40:56Z","timestamp":1760607656185,"version":"build-2065373602"},"reference-count":86,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejinme.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1016\/j.ejim.2014.01.016","type":"journal-article","created":{"date-parts":[[2014,2,12]],"date-time":"2014-02-12T10:30:20Z","timestamp":1392201020000},"page":"213-220","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["How to manage prasugrel and ticagrelor in daily practice"],"prefix":"10.1016","volume":"25","author":[{"given":"Fanny","family":"Bonhomme","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1546-0774","authenticated-orcid":false,"given":"Pierre","family":"Fontana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Luc","family":"Reny","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejim.2014.01.016_bb0005","doi-asserted-by":"crossref","first-page":"S199","DOI":"10.1378\/chest.08-0672","article-title":"Antiplatelet drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)","volume":"133","author":"Patrono","year":"2008","journal-title":"Chest"},{"key":"10.1016\/j.ejim.2014.01.016_bb0010","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.jacc.2008.05.032","article-title":"Incidence and clinical impact of dual non-responsiveness to aspirin and clopidogrel in patients with drug-eluting stents","volume":"52","author":"Gori","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2014.01.016_bb0015","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.ejim.2009.09.005","article-title":"New antiplatelet agents: why they are needed","volume":"20","author":"Franchini","year":"2009","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.ejim.2014.01.016_bb0020","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1111\/j.1476-5381.2009.00555.x","article-title":"Pharmacokinetic, pharmacodynamic and clinical profile of novel antiplatelet drugs targeting vascular diseases","volume":"159","author":"Siller-Matula","year":"2010","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.ejim.2014.01.016_bb0025","first-page":"232","article-title":"Switching antiplatelet regimens: alternatives to clopidogrel in patients with acute coronary syndrome undergoing PCI: a review of the literature and practical considerations for the interventional cardiologist","volume":"81","author":"Azmoon","year":"2013","journal-title":"Catheter Cardiovasc Interv"},{"key":"10.1016\/j.ejim.2014.01.016_bb0030","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1093\/eurheartj\/ehr236","volume":"32","author":"Hamm","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2014.01.016_bb0035","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1093\/eurheartj\/ehs215","article-title":"ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation","volume":"33","author":"Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC)","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2014.01.016_bb0040","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1093\/eurheartj\/ehm545","article-title":"Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease","volume":"29","author":"Wallentin","year":"2008","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2014.01.016_bb0045","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/01.fjc.0000210069.47205.c0","article-title":"The platelet inhibitory effects and pharmacokinetics of prasugrel after administration of loading and maintenance doses in healthy subjects","volume":"47","author":"Jakubowski","year":"2006","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.ejim.2014.01.016_bb0050","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1161\/CIRCULATIONAHA.105.559088","volume":"112","author":"von Beckerath","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2014.01.016_bb0055","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1177\/0091270010367429","article-title":"Integrated analysis of pharmacokinetic data across multiple clinical pharmacology studies of prasugrel, a new thienopyridine antiplatelet agent","volume":"51","author":"Small","year":"2011","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.ejim.2014.01.016_bb0060","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1056\/NEJMe0906549","article-title":"Ticagrelor\u2014is there need for a new player in the antiplatelet-therapy field?","volume":"361","author":"Sch\u00f6mig","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2014.01.016_bb0065","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1111\/j.1538-7836.2009.03527.x","article-title":"Ticagrelor binds to human P2Y12 independently from ADP but antagonizes ADP-induced receptor signaling and platelet aggregation","volume":"7","author":"v Van Giezen","year":"2009","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.ejim.2014.01.016_bb0070","first-page":"197","article-title":"Antiplatelet therapy in acute coronary syndromes: focus on ticagrelor","volume":"1","author":"Birkeland","year":"2010","journal-title":"J Blood Med"},{"key":"10.1016\/j.ejim.2014.01.016_bb0075","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s00228-009-0778-5","article-title":"Pharmacokinetics, pharmacodynamics, tolerability and safety of single ascending doses of ticagrelor, a reversibly binding oral P2Y12 receptor antagonist, in healthy subjects","volume":"66","author":"Teng","year":"2010","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.ejim.2014.01.016_bb0080","doi-asserted-by":"crossref","first-page":"66.e9","DOI":"10.1016\/j.ahj.2006.10.010","article-title":"A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation","volume":"153","author":"Brandt","year":"2007","journal-title":"Am Heart J"},{"key":"10.1016\/j.ejim.2014.01.016_bb0085","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.1161\/CIRCULATIONAHA.107.740324","volume":"116","author":"Wiviott","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2014.01.016_bb0090","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.jacc.2011.04.017","article-title":"High on-treatment platelet reactivity after prasugrel loading dose and cardiovascular events after percutaneous coronary intervention in acute coronary syndromes","volume":"58","author":"Bonello","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2014.01.016_bb0095","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1016\/j.jacc.2013.07.101","article-title":"Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding","volume":"62","author":"Tantry","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2014.01.016_bb0100","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1016\/j.jacc.2012.02.042","article-title":"Recovery of platelet function after discontinuation of prasugrel or clopidogrel maintenance dosing in aspirin-treated patients with stable coronary disease: the recovery trial","volume":"59","author":"Price","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2014.01.016_bb0105","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1161\/CIRCULATIONAHA.109.912550","article-title":"Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET\/OFFSET study","volume":"120","author":"Gurbel","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2014.01.016_bb0110","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2014.01.016_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtcvs.2012.07.059","article-title":"Transfusion outcomes in patients undergoing coronary artery bypass grafting treated with prasugrel or clopidogrel: TRITON-TIMI 38 retrospective data analysis","volume":"145","author":"Goodnough","year":"2013","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.ejim.2014.01.016_bb0120","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S0140-6736(08)60422-5","volume":"371","author":"Wiviott","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2014.01.016_bb0125","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1056\/NEJMoa1205512","article-title":"Prasugrel versus clopidogrel for acute coronary syndromes without revascularization","volume":"367","author":"Roe","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2014.01.016_bb0130","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2014.01.016_bb0135","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.jacc.2010.10.029","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial","volume":"57","author":"Held","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2014.01.016_bb0140","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.ijcard.2012.01.080","article-title":"Incidence and predictors of coronary stent thrombosis: evidence from an international collaborative meta-analysis including 30 studies, 221,066 patients, and 4276 thromboses","volume":"167","author":"D'Ascenzo","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.ejim.2014.01.016_bb0145","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.ejcts.2010.08.019","article-title":"Guidelines on myocardial revascularization","volume":"38","author":"Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC)","year":"2010","journal-title":"Eur J Cardiothorac Surg"},{"key":"10.1016\/j.ejim.2014.01.016_bb0150","first-page":"208","article-title":"The use of antiplatelet therapy in the outpatient setting: Canadian Cardiovascular Society Guidelines Executive Summary","volume":"27","author":"Bell","year":"2011","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.ejim.2014.01.016_bb0155","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1161\/CIRCINTERVENTIONS.112.972323","article-title":"Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction","volume":"5","author":"Alexopoulos","year":"2012","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.ejim.2014.01.016_bb0160","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1016\/j.jacc.2013.01.024","article-title":"Comparison of prasugrel and ticagrelor loading doses in STEMI patients: the rapid activity of platelet inhibitor drugs (RAPID) primary PCI study","volume":"61","author":"Parodi","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2014.01.016_bb0165","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1161\/CIRCINTERVENTIONS.111.967463","article-title":"Duration of dual antiplatelet therapy and long-term clinical outcome after coronary drug-eluting stent implantation: landmark analyses from the CREDO-Kyoto PCI\/CABG Registry Cohort-2","volume":"5","author":"Tada","year":"2012","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.ejim.2014.01.016_bb0170","doi-asserted-by":"crossref","first-page":"3078","DOI":"10.1093\/eurheartj\/ehs318","article-title":"Clinical impact of extended dual antiplatelet therapy after percutaneous coronary interventions in the drug-eluting stent era: a meta-analysis of randomized trials","volume":"33","author":"Cassese","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2014.01.016_bb0175","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1161\/CIRCULATIONAHA.111.071589","article-title":"Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial","volume":"125","author":"Valgimigli","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2014.01.016_bb0180","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1177\/0091270012448398","article-title":"Optimal duration of dual-antiplatelet therapy following drug-eluting stent implantation: a meta-analysis","volume":"53","author":"Zhang","year":"2013","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.ejim.2014.01.016_bb0185","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1177\/0091270009337942","article-title":"Population pharmacokinetic analyses to evaluate the influence of intrinsic and extrinsic factors on exposure of prasugrel active metabolite in TRITON-TIMI 38","volume":"49","author":"Wrishko","year":"2009","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.ejim.2014.01.016_bb0190","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1016\/j.jacc.2012.08.964","article-title":"Reduction in platelet reactivity with prasugrel 5mg in low-body-weight patients is noninferior to prasugrel 10mg in higher-body-weight patients: results from the FEATHER trial","volume":"60","author":"Erlinge","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2014.01.016_bb0195","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1161\/CIRCULATIONAHA.113.002303","article-title":"Elderly patients with acute coronary syndromes managed without revascularization: insights into the safety of long-term dual antiplatelet therapy with reduced-dose prasugrel versus standard-dose clopidogrel","volume":"128","author":"Roe","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2014.01.016_bb0200","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1161\/CIRCULATIONAHA.108.791061","volume":"118","author":"Wiviott","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2014.01.016_bb0205","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1093\/eurheartj\/ehq494","article-title":"A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial","volume":"32","author":"Angiolillo","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2014.01.016_bb0210","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1161\/CIRCULATIONAHA.109.933796","article-title":"Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial","volume":"122","author":"James","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2014.01.016_bb0215","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1161\/CIRCULATIONAHA.110.974683","article-title":"Ticagrelor in the renal dysfunction subgroup: subjugated or substantiated?","volume":"122","author":"Montalescot","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2014.01.016_bb0220","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.3748\/wjg.v18.i18.2161","article-title":"Clopidogrel and proton pump inhibitors \u2014 where do we stand in 2012?","volume":"18","author":"Drepper","year":"2012","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.ejim.2014.01.016_bb0225","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa1007964","article-title":"Clopidogrel with or without omeprazole in coronary artery disease","volume":"363","author":"Bhatt","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2014.01.016_bb0230","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.ijcard.2012.03.085","article-title":"No consistent evidence of differential cardiovascular risk amongst proton-pump inhibitors when used with clopidogrel: meta-analysis","volume":"167","author":"Kwok","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.ejim.2014.01.016_bb0235","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1161\/CIRCULATIONAHA.111.032912","article-title":"Association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor: insights from the platelet inhibition and patient outcomes trial","volume":"125","author":"Goodman","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2014.01.016_bb0240","doi-asserted-by":"crossref","first-page":"667","DOI":"10.2174\/138920010794233521","article-title":"Impact of genetic polymorphisms and drug\u2013drug interactions on clopidogrel and prasugrel response variability","volume":"11","author":"Ancrenaz","year":"2010","journal-title":"Curr Drug Metab"},{"key":"10.1016\/j.ejim.2014.01.016_bb0245","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/j.1742-7843.2012.00932.x","article-title":"Pharmacokinetic interaction between prasugrel and ritonavir in healthy volunteers","volume":"112","author":"Ancrenaz","year":"2013","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1016\/j.ejim.2014.01.016_bb0250","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1124\/dmd.110.037143","article-title":"In vitro evaluation of potential drug\u2013drug interactions with ticagrelor: cytochrome P450 reaction phenotyping, inhibition, induction, and differential kinetics","volume":"39","author":"Zhou","year":"2011","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.ejim.2014.01.016_bb0255","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s00228-012-1369-4","article-title":"Pharmacokinetic interaction studies of co-administration of ticagrelor and atorvastatin or simvastatin in healthy volunteers","volume":"69","author":"Teng","year":"2013","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.ejim.2014.01.016_bb0260","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.amjcard.2010.08.067","article-title":"Prevalence, predictors, and long-term prognosis of premature discontinuation of oral antiplatelet therapy after drug eluting stent implantation","volume":"107","author":"Rossini","year":"2011","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ejim.2014.01.016_bb0265","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.1093\/eurheartj\/ehp275","article-title":"Stent thrombosis after drug-eluting stent implantation: incidence, timing, and relation to discontinuation of clopidogrel therapy over a 4-year period","volume":"30","author":"Schulz","year":"2009","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2014.01.016_bb0270","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.jcin.2012.02.014","article-title":"Contemporary incidence and predictors of stent thrombosis and other major adverse cardiac events in the year after XIENCE V implantation: results from the 8,061-patient XIENCE V United States study","volume":"5","author":"Naidu","year":"2012","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.ejim.2014.01.016_bb0275","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1093\/eurheartj\/ehp337","article-title":"Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery","volume":"30","author":"Task Force for Preoperative Cardiac Risk Assessment","year":"2009","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2014.01.016_bb0280","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1136\/hrt.2011.224519","article-title":"Non-cardiac surgery in patients with coronary stents: the RECO study","volume":"97","author":"Albaladejo","year":"2011","journal-title":"Heart"},{"key":"10.1016\/j.ejim.2014.01.016_bb0285","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1161\/CIRCULATIONAHA.108.813667","article-title":"Safety of short-term discontinuation of antiplatelet therapy in patients with drug-eluting stents","volume":"119","author":"Eisenberg","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2014.01.016_bb0290","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1212\/WNL.0b013e31820d62b5","article-title":"Increased risk of stroke after discontinuation of acetylsalicylic acid: a UK primary care study","volume":"76","author":"Garc\u00eda Rodr\u00edguez","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.ejim.2014.01.016_bb0295","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1093\/eurheartj\/ehn104","article-title":"The effect of pre-operative aspirin on bleeding, transfusion, myocardial infarction, and mortality in coronary artery bypass surgery: a systematic review of randomized and observational studies","volume":"29","author":"Sun","year":"2008","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2014.01.016_bb0300","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.jtcvs.2009.04.052","article-title":"Antiplatelet agents used for early intervention in acute coronary syndrome: myocardial salvage versus bleeding complications","volume":"138","author":"Aranki","year":"2009","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.ejim.2014.01.016_bb0305","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1136\/hrt.2004.058396","article-title":"Does clopidogrel affect outcome after coronary artery bypass grafting? A meta-analysis","volume":"92","author":"Purkayastha","year":"2006","journal-title":"Heart"},{"key":"10.1016\/j.ejim.2014.01.016_bb0310","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S0735-1097(03)00622-3","article-title":"Clinical outcome of patients undergoing non-cardiac surgery in the two months following coronary stenting","volume":"42","author":"Wilson","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2014.01.016_bb0315","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1136\/heartjnl-2012-302717","article-title":"Prevalence, indications and appropriateness of antiplatelet therapy in patients operated for acute aortic dissection: associations with bleeding complications and mortality","volume":"99","author":"Hansson","year":"2013","journal-title":"Heart"},{"key":"10.1016\/j.ejim.2014.01.016_bb0320","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0049-3848(02)00387-0","article-title":"Perioperative anticoagulation management in patients who are receiving oral anticoagulant therapy: a practical guide for clinicians","volume":"108","author":"Douketis","year":"2002","journal-title":"Thromb Res"},{"key":"10.1016\/j.ejim.2014.01.016_bb0325","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.jacc.2007.01.003","volume":"49","author":"Grines","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2014.01.016_bb0330","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1097\/EJA.0b013e328360c442","article-title":"Management of antithrombotic therapies in patients scheduled for eye surgery","volume":"30","author":"Bonhomme","year":"2013","journal-title":"Eur J Anaesthesiol"},{"key":"10.1016\/j.ejim.2014.01.016_bb0335","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1055\/s-0030-1256317","article-title":"Endoscopy and antiplatelet agents. European Society of Gastrointestinal Endoscopy (ESGE) Guideline","volume":"43","author":"Bousti\u00e8re","year":"2011","journal-title":"Endoscopy"},{"key":"10.1016\/j.ejim.2014.01.016_bb0340","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1097\/SLA.0b013e318250504e","article-title":"Should more patients continue aspirin therapy perioperatively?","volume":"255","author":"Gerstein","year":"2012","journal-title":"Ann Surg"},{"key":"10.1016\/j.ejim.2014.01.016_bb0345","doi-asserted-by":"crossref","first-page":"e326S","DOI":"10.1378\/chest.11-2298","article-title":"Perioperative management of antithrombotic therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Douketis","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.ejim.2014.01.016_bb0350","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1160\/TH10-04-0217","volume":"105","author":"Korte","year":"2011","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.ejim.2014.01.016_bb0355","first-page":"1042","article-title":"Antiplatelet therapy and cardiac surgery: review of recent evidence and clinical implications","volume":"29","author":"Fitchett","year":"2013","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.ejim.2014.01.016_bb0360","article-title":"Focused 2012 Update of the Canadian Cardiovascular Society Guidelines for the Use of Antiplatelet Therapy","volume":"23","author":"Tanguay","year":"2013","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.ejim.2014.01.016_bb0365","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/HPC.0b013e31826c53cd","article-title":"Recommendations for management of antiplatelet therapy in patients undergoing elective noncardiac surgery after coronary stent implantation","volume":"11","author":"Huang","year":"2012","journal-title":"Crit Pathw Cardiol"},{"key":"10.1016\/j.ejim.2014.01.016_bb0370","doi-asserted-by":"crossref","first-page":"880","DOI":"10.2174\/1389450111314080008","article-title":"Perioperative handling of antiplatelet drugs. A critical appraisal","volume":"14","author":"Di Minno","year":"2013","journal-title":"Curr Drug Targets"},{"key":"10.1016\/j.ejim.2014.01.016_bb0375","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.amjcard.2012.04.016","article-title":"Safety of \u201cbridging\u201d with eptifibatide for patients with coronary stents before cardiac and non-cardiac surgery","volume":"110","author":"Rassi","year":"2012","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ejim.2014.01.016_bb0380","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1111\/j.1538-7836.2011.04456.x","article-title":"Management of patients with recently implanted coronary stents on dual antiplatelet therapy who need to undergo major surgery","volume":"9","author":"Savonitto","year":"2011","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.ejim.2014.01.016_bb0385","first-page":"575","article-title":"Bridging with glycoprotein IIb\/IIIa inhibitors for periprocedural management of antiplatelet therapy in patients with drug eluting stents","volume":"79","author":"Morrison","year":"2011","journal-title":"Catheter Cardiovasc Interv"},{"key":"10.1016\/j.ejim.2014.01.016_bb0390","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1586\/14779072.2013.837701","article-title":"Cangrelor: a review on pharmacology and clinical trial development","volume":"11","author":"Franchi","year":"2013","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"10.1016\/j.ejim.2014.01.016_bb0395","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1160\/TH09-11-0799","article-title":"Platelet function testing and risk of bleeding complications","volume":"103","author":"Ferreiro","year":"2010","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.ejim.2014.01.016_bb0400","doi-asserted-by":"crossref","first-page":"A35A","DOI":"10.1016\/j.amjcard.2008.11.022","article-title":"Monitoring platelet function to reduce the risk of ischemic and bleeding complications","volume":"103","author":"Price","year":"2009","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ejim.2014.01.016_bb0405","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1161\/CIRCINTERVENTIONS.111.967208","volume":"5","author":"Mahla","year":"2012","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.ejim.2014.01.016_bb0410","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.jjcc.2009.12.014","article-title":"Impact of anticoagulant therapy with dual antiplatelet therapy on prognosis after treatment with drug-eluting coronary stents","volume":"55","author":"Uchida","year":"2010","journal-title":"J Cardiol"},{"key":"10.1016\/j.ejim.2014.01.016_bb0415","doi-asserted-by":"crossref","first-page":"C49","DOI":"10.1016\/j.amjcard.2009.06.016","article-title":"Optimizing antithrombotic strategies in patients with concomitant indications for warfarin undergoing coronary artery stenting","volume":"104","author":"Zinn","year":"2009","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ejim.2014.01.016_bb0420","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1093\/icvts\/ivs104","article-title":"What do you do with the antiplatelet agents in patients with drug eluting stents who then receive a mechanical valve?","volume":"15","author":"Rossi","year":"2012","journal-title":"Interact Cardiovasc Thorac Surg"},{"key":"10.1016\/j.ejim.2014.01.016_bb0425","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1160\/TH09-08-0580","article-title":"Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and\/or undergoing percutaneous coronary intervention\/stenting","volume":"103","author":"Lip","year":"2010","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.ejim.2014.01.016_bb0430","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1161\/CIRCULATIONAHA.106.618066","article-title":"Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry","volume":"113","author":"Spertus","year":"2006","journal-title":"Circulation"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620514000405?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620514000405?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T09:27:09Z","timestamp":1760606829000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620514000405"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":86,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["S0953620514000405"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2014.01.016","relation":{},"ISSN":["0953-6205"],"issn-type":[{"type":"print","value":"0953-6205"}],"subject":[],"published":{"date-parts":[[2014,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"How to manage prasugrel and ticagrelor in daily practice","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2014.01.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}